RxDoctor Payments Data

Krystal Vonfeldt, DO

Family Medicine · Duncan, OKNPI 1114294741

Payments from drug & device makers

$990in general payments, 2019–2025

Across 78 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$146
  • Merck$140
  • Biohaven Pharmaceuticals, Inc.$120
  • Novartis$91
  • GSK$89
  • Sunovion Pharmaceuticals Inc.$73
  • plus $331 from 10 others

What the payments were for

  • Food & beverage$98499%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$990 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$50,981
Medicare patients
141
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide177$208,878
EliquisApixaban203$146,250
JardianceEmpagliflozin80$92,638
OzempicSemaglutide56$57,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$46,783
Tresiba Flextouch U-200Insulin Degludec40$39,220
JanuviaSitagliptin Phosphate36$33,974
TrulicityDulaglutide28$32,898
LinzessLinaclotide56$31,752
XareltoRivaroxaban36$31,472
FarxigaDapagliflozin Propanediol13$15,972
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$13,795
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,654
Tresiba Flextouch U-100Insulin Degludec16$10,006
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$58$241,777205 claims
PfizerEliquis$40$146,250203 claims
Boehringer IngelheimJardiance$56$92,63880 claims
Novo NordiskOzempic$38$57,24756 claims
GSKTrelegy Ellipta, Anoro Ellipta$89$54,24581 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$146$36,61152 claims
MerckJanuvia$140$33,97436 claims
Johnson & JohnsonXarelto$29$31,47236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Duncan

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →